According to the company, the data from both studies demonstrated that a test using the Parsortix system can differentiate between women with a malignant pelvic mass and those with benign tumours with a high degree of sensitivity of up to 95%, while at the same time achieving a higher specificity.

The RNA-based test is said to combine both high sensitivity and high specificity.

 The successful results will allow Angle to advance into the next phase of development of a commercial blood test, helping to enter an estimated market size of £300m per annum.

Parsortix, which is a cell separation technology, allows a liquid biopsy to be used to offer the cells of interest.

It is based on a microfluidic device that captures live cells based on a combination of their size and compressibility.

Parsortix blood test will help in the diagnosis of ovarian cancer prior to a patient undergoing a biopsy or surgery. It will also enable to identify targets on the tumour that may be used to inform treatment strategies

To meet European CE mark and the US FDA regulatory requirements, the company will validate the optimised test in a separate set of patients through carrying out appropriately powered validation studies.

Upon the successful completion of validation studies, the firm will commercially market Parsortix-based pelvic mass test in the US and Europe.

Angle founder and chief executive Andrew Newland said: "Angle’s first large scale clinical studies of 400 patients have demonstrated positive results with the potential to out-perform current standard of care.

“This success enables Angles to move forward into the validation phase for the use of Parsortix in its first clinical application.”

Image: The Parsortix-based blood test has showed positive headline results in the US and European ovarian cancer studies. Photo: courtesy of Suwit Ritjaroon /